Sage Therapeutics (NASDAQ:SAGE) Issues Quarterly Earnings Results

Sage Therapeutics (NASDAQ:SAGE) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.

Sage Therapeutics Trading Down 0.4 %

NASDAQ SAGE opened at $7.16 on Thursday. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $27.39. The stock’s fifty day moving average price is $6.34 and its 200-day moving average price is $6.93. The stock has a market cap of $437.98 million, a P/E ratio of -1.28 and a beta of 0.94.

Analyst Ratings Changes

Several equities research analysts have weighed in on SAGE shares. Truist Financial dropped their price objective on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, October 30th. Wedbush reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday. Scotiabank reduced their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 target price (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday. Finally, Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $9.65.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.